Utilization of Treg Cells in Solid Organ Transplantation

Organ transplants have been a life-saving form of treatment for many patients who are facing end stage organ failure due to conditions such as diabetes, hypertension, various congenital diseases, idiopathic diseases, traumas, and other end-organ failure. While organ transplants have been monumental...

Full description

Saved in:

Bibliographic Details
Published in:	Frontiers in immunology Vol. 13; p. 746889
Main Authors:	Juneja, Tanya, Kazmi, Maria, Mellace, Michael, Saidi, Reza F
Format:	Journal Article
Language:	English
Published:	Switzerland Frontiers Media S.A 04-02-2022
Subjects:	Autoimmune Diseases - therapy Clinical Studies as Topic Graft Rejection - immunology Graft Rejection - prevention & control Humans Immunology immunosuppression Immunosuppression Therapy - methods kidney Organ Transplantation - methods rejection solid T-Lymphocytes, Regulatory - immunology T-regs transplant organ kidney solid immunosuppression transplant T-regs rejection
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Organ transplants have been a life-saving form of treatment for many patients who are facing end stage organ failure due to conditions such as diabetes, hypertension, various congenital diseases, idiopathic diseases, traumas, and other end-organ failure. While organ transplants have been monumental in treatment for these conditions, the ten year survival and long-term outcome for these patients is poor. After receiving the transplant, patients receive a multi-drug regimen of immunosuppressants. These drugs include cyclosporine, mTOR inhibitors, corticosteroids, and antibodies. Polyclonal antibodies, which inhibit the recipient's B lymphocytes, and antibodies targeting host cytokine inhibitors which prevent activation of B cells by T cells. Use of these drugs suppresses the immune system and increases the risk of opportunistic pathogen infections, tumors, and further damage to the transplanted organs and vasculature. Many regulatory mechanisms are present in organs to prevent the development of autoimmune disease, and Tregs are central to these mechanisms. Tregs secrete suppressive cytokines such as IL-10, TGF-B, and IL-35 to suppress T cells. Additionally, Tregs can bind to target cells to induce cell cycle arrest and apoptosis and can inhibit induction of IL-2 mRNA in target T cells. Tregs also interact with CTLA-4 and CD80/CD86 on antigen presenting cells (APCs) to prevent their binding to CD28 present on T cells. Due to their various immunosuppressive capabilities, Tregs are being examined as a possible treatment for patients that receive organ transplants to minimize rejection and prevent the negative outcomes. Several studies in which participants were given Tregs after undergoing organ transplantations were reviewed to determine the efficacy and safety of using Tregs in solid organ transplantation to prevent adverse outcomes.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 Edited by: Stanislaw Stepkowski, University of Toledo, United States This article was submitted to Alloimmunity and Transplantation, a section of the journal Frontiers in Immunology Reviewed by: Jing Li, Stanford University School of Medicine, United States; Arimelek Cortés Hernández, National Autonomous University of Mexico, Mexico
ISSN:	1664-3224 1664-3224
DOI:	10.3389/fimmu.2022.746889